Frequency of Incomplete Atypical Femoral Fractures in Asymptomatic Patients on Long-Term Bisphosphonate Therapy
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The purpose of our study was to determine the frequency and imaging features of atypical femoral fractures in a consecutive asymptomatic patient population on long-term bisphosphonate treatment and search for distinguishing clinical and laboratory parameters in the subset of patients with fractures. SUBJECTS AND METHODS: Two hundred femoral radiographs in 100 asymptomatic patients (93 women and seven men; age range, 47-94 years; mean age, 69.3 years) were prospectively reviewed by two radiologists. All patients had received bisphosphonate treatment for at least 3 years and had no history of pain or recent trauma. MRI studies were performed when a fracture was suspected on radiographs. Bone mineral density, serum calcium, albumin, 25-hydroxy vitamin D, intact parathyroid hormone (iPTH), serum C-telopeptide, and urine N-telopeptide values were obtained. RESULTS: Two of 100 patients (2%) had three insufficiency fractures. Both patients, 50 and 57 years old, were white, active, and had been receiving bisphosphonate therapy for 8 years. The patient with bilateral atypical femoral fractures showed typical features of bisphosphonate-related incomplete atypical femoral fractures. MRI confirmed the radiographic findings in both patients. The two patients with incomplete atypical femoral fractures were significantly younger than those without atypical femoral fractures. There were no significant differences among the fracture and nonfracture groups in terms of clinical or laboratory results, except for mean iPTH, which was significantly decreased in the fracture group. CONCLUSION: The 2% frequency of incomplete atypical femoral fractures in asymptomatic patients on long-term bisphosphonate therapy is higher than suggested in the literature. Aside from age and mean iPTH, there were no significant differences in clinical or laboratory data between the two groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147 · cited 2×
“This article has since been questioned in the literature because of its many limitations [33, 34] and is in contradistinction to recent reports in which a significant number of bisphosphonate-associated fractures have been collected in a relatively short time [6, 10, 12, 16, 23, 24, 35, 36].”
BackgroundResultBisphosphonates: Mechanism of action and role in clinical practice
Drake, M. T., Clarke, B. L., & Khosla, S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1032 · Cited by 1,644 · cited 2×
“© American Roentgen Ray Society B isphosphonates are the most commonly prescribed drugs for the prevention and treatment of osteoporosis and are highly effective in reducing the risk of vertebral and hip fractures [1, 2].”
BackgroundBlack, D. M., Schwartz, A. V., Ensrud, K. E., Cauley, J. A., Levis, S., Quandt, S. A., Satterfield, S., Wallace, R. B., Bauer, D. C., Palermo, L., et al. (2006) · JAMA · doi:10.1001/jama.296.24.2927 · Cited by 1,407 · cited 1×
“Several published trials have established the efficacy of alendronate, risedronate, and zoledronic acid in reducing vertebral and hip fractures and ibandronate in reducing vertebral fractures [1, 30, 31].”
BackgroundAtypical fractures of the femur and bisphosphonate therapy
Giusti, A., Hamdy, N. A. T., & Papapoulos, S. E. (2010) · Bone · doi:10.1016/j.bone.2010.05.019 · Cited by 295
Cited by
Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Crandall, C. J., Newberry, S. J., Diamant, A., Lim, Y.-W., Gellad, W. F., Booth, M. J., Motala, A., & Shekelle, P. G. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0317 · Cited by 254
Lloyd, A. A., Gludovatz, B., Riedel, C., Luengo, E. A., Saiyed, R., Marty, E., Lorich, D. G., Lane, J. M., Ritchie, R. O., Busse, B., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704460114 · Cited by 158
“The incidence of “incomplete” AFFs in asymptomatic patients is much higher than that of complete catastrophic atypical fractures (35), suggesting that the majority of patients who experience a partial AFF may recover through healing of the incomplete fracture before it propagates.”
BackgroundBisphosphonate-related atypical femoral fracture: Managing a rare but serious complication
Silverman, S., Kupperman, E., & Bukata, S. (2018) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.85a.17119 · Cited by 34
Metadata
- Authors
- La Rocca Vieira, R., Rosenberg, Z. S., Allison, M. B., Im, S. A., Babb, J., & Peck, V.
- Venue
- American Journal of Roentgenology
- Publisher
- American Roentgen Ray Society
- Published
- 2012-05
- Volume
- 198
- Issue
- 5
- Pages
- 1144-1151
- ISSN
- 0002-9580 (ISSN-L)
- 0361-803X
- 1546-3141
- OpenAlex
- W2142378010
- Cited by
- 49
- References
- 5
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Frequency of Incomplete Atypical Femoral Fractures in Asymptomatic Patients on Long-Term Bisphosphonate Therapy. https://app.cochat.ai/papers/10.2214/ajr.11.7442
- The paper
- La Rocca Vieira, R., Rosenberg, Z. S., Allison, M. B., Im, S. A., Babb, J., & Peck, V. (2012). Frequency of Incomplete Atypical Femoral Fractures in Asymptomatic Patients on Long-Term Bisphosphonate Therapy. American Journal of Roentgenology. https://doi.org/10.2214/ajr.11.7442
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.